What are the benfits of concomitant threatment with bevacizumab for patients undergoing re-irradiation for recurrent glioblastoma?

Updated: Jul 01, 2019
  • Author: Jeffrey N Bruce, MD; Chief Editor: Herbert H Engelhard, III, MD, PhD, FACS, FAANS  more...
  • Print
Answer

Fleischmann et al reported that in patients undergoing re-irradiation for recurrent glioblastoma, concomitant treatment with bevacizumab significantly reduced the rate of radiation toxicity, both in the short and the long term. Bevacizumab was given in a dose of 10 mg/kg on days 1 and 15 of re-irradiation therapy. [77]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!